{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T07:31:01Z","timestamp":1788679861223,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd002203.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T00:00:00Z","timestamp":1708992000000}}],"reference-count":141,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002203.pub5","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T06:52:18Z","timestamp":1709016738000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Macrolide antibiotics (including azithromycin) for cystic fibrosis"],"prefix":"10.1002","volume":"2024","author":[{"given":"Kevin W","family":"Southern","sequence":"additional","affiliation":[{"name":"Alder Hey Children's NHS Foundation Trust; Liverpool UK"},{"name":"Department of Women's and Children's Health; University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Solis-Moya","sequence":"additional","affiliation":[{"name":"Servicio de Neumolog\u00eda; Hospital Nacional de Ni\u00f1os; San Jos\u00e9 Costa Rica"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominiki","family":"Kurz","sequence":"additional","affiliation":[{"name":"University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherie","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Child Health, Obstetrics & Gynaecology (COG), School of Medicine; University of Nottingham; Nottingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,27]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD002203.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thx.2005.057950","article-title":"Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial","volume":"61","author":"Clement","year":"2006","journal-title":"Thorax"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub5-BIB0002|cit2","first-page":"S68","article-title":"Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a mulicenter, randomized, double-blind, placebo-controlled trial","volume":"4","author":"Clement","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 28","key":"10.1002\/14651858.CD002203.pub5-BIB0003|cit3","first-page":"285","article-title":"Long term effects and clinical outcome of low-dose azithromycin in young patients with cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"40","author":"Clement","year":"2005","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0004|cit4","unstructured":"Prevention of bronchiectasis in infants with cystic fibrosis trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12610001072000"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1016\/S1569-1993(21)01913-5","article-title":"Relationships between antibiotic exposure and early lung microbial colonization in infants with cystic fibrosis","volume":"20 Suppl 2","author":"Caparros-Martin","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1016\/S1569-1993(21)02000-2","article-title":"Outcomes from COMBAT CF: a phase 3 multicenter, randomized, placebo-controlled trial of azithromycin in primary prevention of radiologically defined bronchiectasis in infants with cystic fibrosis","volume":"20 Suppl 2","author":"Foti","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0007|cit7","unstructured":"Prevention of Bronchiectasis in Infants With Cystic Fibrosis www.clinicaltrials.gov 2011"},{"issue":"8","key":"10.1002\/14651858.CD002203.pub5-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-2600(22)00165-5","article-title":"The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial","volume":"10","author":"Stick","year":"2022","journal-title":"Lancet Respiratory Medicine"},{"issue":"9338","key":"10.1002\/14651858.CD002203.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(02)11081-6","article-title":"Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial","volume":"360","author":"Equi","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0010|cit10","first-page":"307","article-title":"A prospective, double-blind, randomised, placebo controlled, crossover trial of long term azithromycin in children [abstract]","volume":"Suppl 22","author":"Equi","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0011|cit11","first-page":"iii38","article-title":"A prospective, double-blind, randomised, placebo controlled, crossover trial of azithromycin in paediatric cystic fibrosis","volume":"Suppl 3","author":"Equi","year":"2002","journal-title":"Thorax"},{"issue":"1","key":"10.1002\/14651858.CD002203.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcf.2009.09.001","article-title":"Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial","volume":"9","author":"Kabra","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0013|cit13","unstructured":"Effect of nebulized azithromycin in cystic fibrosis disease www.who.int\/trialsearch\/Trial2.aspx?TrialID=IRCT2016100930233N1"},{"issue":"6","key":"10.1002\/14651858.CD002203.pub5-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"e96977","DOI":"10.5812\/ijp.96977","article-title":"Nebulized azithromycin versus oral azithromycin as anti-inflammatory therapy in children with cystic fibrosis: a prospective randomized open-label trial","volume":"29","author":"Maneshi","year":"2019","journal-title":"Iranian Journal of Pediatrics"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002203.pub5-BIB0015|cit15","first-page":"A58","article-title":"6-month treatment with azithromycin reduces hospital admissions for respiratory exacerbations in cystic fibrosis","volume":"11","author":"Bell","year":"2006","journal-title":"Respirology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002203.pub5-BIB0016|cit16","first-page":"A11","article-title":"Randomised, prospective double-blind trial of long term daily versus weekly azithromycin in cystic fibrosis","volume":"11","author":"Bell","year":"2006","journal-title":"Respirology"},{"issue":"3","key":"10.1002\/14651858.CD002203.pub5-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1183\/09031936.00163306","article-title":"Daily versus weekly azithromycin in cystic fibrosis patients","volume":"30","author":"McCormack","year":"2007","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0018|cit18","unstructured":"Senini S McCormack J A randomised, prospective double-blind trial of long-term daily versus weekly azithromycin in cystic fibrosis Australian New Zealand Clinical Trials Registry (www.anzctr.org.au) 2005"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0019|cit19","unstructured":"Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF) (TEACH) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02677701"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0020|cit20","first-page":"150","article-title":"Teach: testing the effects of adding chronic azithromycin to inhaled tobramycin; a randomized, controlled, clinical trial","volume":"55 Suppl 2","author":"Nichols","year":"2020","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD002203.pub5-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1136\/thoraxjnl-2021-217782","article-title":"Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial","volume":"77","author":"Nichols","year":"2022","journal-title":"Thorax"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD002203.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1569-1993(08)60095-8","article-title":"Use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa","volume":"7","author":"O'Connor","year":"2008","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0023|cit23","volume-title":"The use of azithromycin in cystic fibrosis patients not infected with Pseudomonas aeruginosa","author":"O'Connor","year":"2009"},{"issue":"2","key":"10.1002\/14651858.CD002203.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1016\/j.jcf.2020.11.005","article-title":"Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis","volume":"20","author":"Magaret","year":"2021","journal-title":"Journal of Cystic Fibrosis"},{"issue":"9","key":"10.1002\/14651858.CD002203.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1164\/rccm.201802-0215OC","article-title":"Azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial","volume":"198","author":"Mayer-Hamblett","year":"2018","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002203.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1164\/rccm.v199erratum2","article-title":"Erratum: azithromycin for early pseudomonas infection in cystic fibrosis. The OPTIMIZE randomized trial","volume":"199","author":"Mayer-Hamblett","year":"2019","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3389\/fphar.2018.00595","article-title":"Metabolomic analysis by nuclear magnetic resonance spectroscopy as a new approach to understanding inflammation and monitoring of pharmacological therapy in children and young adults with cystic fibrosis","volume":"9","author":"Montuschi","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0028|cit28","unstructured":"Optimizing treatment for early pseudomonas aeruginosa infection in cystic fibrosis clinicaltrials.gov\/show\/NCT02054156"},{"issue":"Suppl 47","key":"10.1002\/14651858.CD002203.pub5-BIB0029|cit29","first-page":"380","article-title":"Efficacy and safety of azithromycin for treatment of early pseudomonas in cystic fibrosis: the OPTIMIZE trial","volume":"52","author":"Ramsey","year":"2017","journal-title":"Pediatric Pulmonology"},{"issue":"2","key":"10.1002\/14651858.CD002203.pub5-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s10238-005-0070-7","article-title":"Autoantibodies against bactericidal\/permeability-increasing protein (BPI-ANCA) in cystic fibrosis patients treated with azithromycin","volume":"5","author":"Rotschild","year":"2005","journal-title":"Clinical and Experimental Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002203.pub5-BIB0031|cit31","first-page":"60","article-title":"The benefits of azithromycin are not related to its antibacterial action","volume":"11","author":"Magin","year":"2004","journal-title":"Clinical Pulmonary Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002203.pub5-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ppul.20620","article-title":"Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes","volume":"42","author":"Nguyen","year":"2007","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 27","key":"10.1002\/14651858.CD002203.pub5-BIB0033|cit33","first-page":"286","article-title":"Phenotypic characterization of pseudomonas aeruginosa as a potential predictor of clinical response to azithromycin in CF patients","volume":"38","author":"Nguyen","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"13","key":"10.1002\/14651858.CD002203.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD002203.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1164\/rccm.200502-218OC","article-title":"Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis","volume":"172","author":"Saiman","year":"2005","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0036|cit36","first-page":"165","article-title":"What have we learned from further analysis of the U.S. Macrolide Trial?: Subgroup analysis of azithromycin trial","volume":"36 Suppl 25","author":"Saiman","year":"2003","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 33","key":"10.1002\/14651858.CD002203.pub5-BIB0037|cit37","first-page":"377, Abstract n","article-title":"Pulmonary exacerbations in patients 6-18 years old with CF and mild lung disease uninfected with pseudomonas aeruginosa [abstract]","volume":"45","author":"Anstead","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"4","key":"10.1002\/14651858.CD002203.pub5-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.chest.2019.05.017","article-title":"Proteomic profiling to identify blood biomarkers predictive of response to azithromycin in children and adolescents with cystic fibrosis","volume":"156","author":"Dong","year":"2019","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0039|cit39","first-page":"309","article-title":"Pseudomonas aeruginosa choline catabolic mutants in the cystic fibrosis lung","volume":"48","author":"Fitzsimmons","year":"2013","journal-title":"Pediatric Pulmonology"},{"issue":"7","key":"10.1002\/14651858.CD002203.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1128\/JCM.00835-11","article-title":"Lack of association of small-colony-variant Staphylococcus aureus strains with long-term use of azithromycin in patients with cystic fibrosis","volume":"49","author":"Green","year":"2011","journal-title":"Journal of Clinical Microbiology"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0041|cit41","first-page":"292","article-title":"Impact of acute antibiotic usage on the pulmonary exacerbation endpoint in a cystic fibrosis randomized trial","volume":"47 Suppl 35","author":"Hamblett","year":"2012","journal-title":"Pediatric Pulmonology"},{"issue":"1","key":"10.1002\/14651858.CD002203.pub5-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cct.2013.06.004","article-title":"Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials","volume":"36","author":"Mayer-Hamblett","year":"2013","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0043|cit43","unstructured":"Effect of Azithromycin on Lung Function in 6-18 Year-olds With Cystic Fibrosis (CF) Not Infected With P. Aeruginosa https:\/\/clinicaltrials.gov\/show\/NCT00431964 2007"},{"issue":"Suppl 33","key":"10.1002\/14651858.CD002203.pub5-BIB0044|cit44","first-page":"271, Abstract n","article-title":"The effect of azithromycin on inflammatory markers in CG children and adolescents uninfected with pseudomonas aeruginosa [abstract]","volume":"45","author":"Ratjen","year":"2010","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD002203.pub5-BIB0045|cit45","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1378\/chest.12-0628","article-title":"Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa","volume":"142","author":"Ratjen","year":"2012","journal-title":"Chest"},{"issue":"17","key":"10.1002\/14651858.CD002203.pub5-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"303","author":"Saiman","year":"2010","journal-title":"JAMA"},{"issue":"17","key":"10.1002\/14651858.CD002203.pub5-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Online Supplement to 'Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.' [Online]","volume":"303","author":"Saiman","year":"2010","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0048|cit48","unstructured":"Saiman L Anstead M Ratjen F Lands L Effect of azithromycin on lung function in 6-18 year-olds with cystic fibrosis (CF) who are not infected with P. aeruginosa www.clinicaltrials.gov (accessed 04 March 2010) 2007"},{"issue":"7","key":"10.1002\/14651858.CD002203.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ppul.21601","article-title":"Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa","volume":"47","author":"Saiman","year":"2012","journal-title":"Pediatric Pulmonology"},{"issue":"32","key":"10.1002\/14651858.CD002203.pub5-BIB0050|cit50","first-page":"185","article-title":"Azithromycin in CF patients uninfected with pseudomonas aeruginosa [abstract]","volume":"44","author":"Saiman","year":"2009","journal-title":"Pediatric Pulmonology"},{"issue":"11","key":"10.1002\/14651858.CD002203.pub5-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.rmed.2008.03.009","article-title":"Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection","volume":"102","author":"Steinkamp","year":"2008","journal-title":"Respiratory Medicine"},{"issue":"Suppl 30","key":"10.1002\/14651858.CD002203.pub5-BIB0052|cit52","first-page":"300","article-title":"Once weekly azithromycin in cystic fibrosis: a double-blind, randomised trial in patients with chronic pseudomonas aeruginosa infection","volume":"42","author":"Steinkamp","year":"2007","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl","key":"10.1002\/14651858.CD002203.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1569-1993(06)80098-6","article-title":"Clinical and immunomodulatory effects of once weekly azithromycin treatment in cystic fibrosis patients chronically infected with pseudomonas aeruginosa [abstract]","volume":"5","author":"Steinkamp","year":"2006","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0054|cit54","first-page":"289","article-title":"Long-term treatment with azithromycin results in reduced ex-vivo inflammatory cytokine production in adults with cystic fibrosis","volume":"34 Suppl 24","author":"Bell","year":"2002","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0055|cit55","first-page":"280","article-title":"A prospective, randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis; impact on clinical, laboratory and quality of life (QOL) outcomes [abstract]","volume":"30 Suppl 20","author":"Bowler","year":"2000","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0056|cit56","first-page":"A9","article-title":"Long term treatment with azithromycin results in reduced in vitro inflammatory cytokine production in adults with cystic fibrosis","volume":"7 Suppl 1","author":"Bowler","year":"2002","journal-title":"Respirology"},{"issue":"Suppl A","key":"10.1002\/14651858.CD002203.pub5-BIB0057|cit57","first-page":"38","article-title":"Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis","volume":"56","author":"Bowler","year":"2003","journal-title":"Japanese Journal of Antibiotics"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0058|cit58","first-page":"A12","article-title":"A prospective randomised trial of long term azithromycin (AZM) versus placebo in cystic fibrosis (CF): impact on clinical, laboratory and quality of life (QOL) outcomes","volume":"31 Suppl","author":"Seeney","year":"2001","journal-title":"Internal Medicine Journal"},{"issue":"3","key":"10.1002\/14651858.CD002203.pub5-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/thorax.57.3.212","article-title":"Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial","volume":"57","author":"Wolter","year":"2002","journal-title":"Thorax"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0060|cit60","first-page":"A38","article-title":"Azithromycin (AZM) in adults with cystic fibrosis","volume":"6 Suppl","author":"Wolter","year":"2001","journal-title":"Respirology"},{"issue":"Suppl 28","key":"10.1002\/14651858.CD002203.pub5-BIB0061|cit61","first-page":"304","article-title":"Treatment of CF exacerbations based on multiple combination antibiotic susceptibility testing-a randomized, double-blind, controlled clinical trial","volume":"40","author":"Aaron","year":"2005","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub5-BIB0062|cit62","first-page":"157","article-title":"Clinical evidence for combination antibiotic susceptibility testing (synergy testing)","volume":"43","author":"Aaron","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"9484","key":"10.1002\/14651858.CD002203.pub5-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0140-6736(05)67060-2","article-title":"Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial","volume":"366","author":"Aaron","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0064|cit64","first-page":"283","article-title":"Effect of chronic azithromycin on lung function in cystic fibrosis","volume":"28 Suppl 19","author":"Anstead","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"5 Suppl","key":"10.1002\/14651858.CD002203.pub5-BIB0065|cit65","first-page":"A565","article-title":"Effect of azithromycin on lung function, sputum bacteriology, and sputum inflammatory markers in cystic fibrosis","volume":"163","author":"Anstead","year":"2001","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"8","key":"10.1002\/14651858.CD002203.pub5-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1164\/rccm.200311-1508OC","article-title":"Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium","volume":"171","author":"Barker","year":"2005","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0067|cit67","unstructured":"Macrolide antibiotic therapy for patients with cystic fibrosis www.clinicaltrials.gov\/ct2\/show\/NCT00205634"},{"issue":"3 Suppl","key":"10.1002\/14651858.CD002203.pub5-BIB0068|cit68","first-page":"A758","article-title":"The effects of azithromycin therapy on sputum inflammation in CF lung disease [abstract]","volume":"161","author":"App","year":"2000","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub5-BIB0069|cit69","first-page":"S130","article-title":"Low-dose azithromycin therapy reaches sputum drug levels of potential antipseudomonal activity in cystic fibrosis patients","volume":"1","author":"Baumann","year":"2002","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0070|cit70","unstructured":"Baumann U App EM Konig A Sextro W Matthys H von der Hardt H Sputum DNA under long-term therapy with azithromycin Proceedings of the 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm 2000 164"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0071|cit71","unstructured":"Baumann U Fischer JJ Tummler B Sextro W App EM King M Long-term low-dose therapy with azithromycin in CF Proceedings of the 13th International Cystic Fibrosis Congress;2000 June 4-8; Stockholm 2000 165"},{"issue":"2","key":"10.1002\/14651858.CD002203.pub5-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1155\/2004\/747841","article-title":"Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties","volume":"11","author":"Baumann","year":"2004","journal-title":"Canadian Respiratory Journal [Revue canadienne de pneumologie]"},{"issue":"12","key":"10.1002\/14651858.CD002203.pub5-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1128\/AAC.49.12.5013-5017.2005","article-title":"Absolute bioavailability and intracellular pharmacokinetics of azithromycin in patients with cystic fibrosis","volume":"49","author":"Beringer","year":"2005","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"Suppl 27","key":"10.1002\/14651858.CD002203.pub5-BIB0074|cit74","first-page":"285","article-title":"Controlled pharmacokinetic study of azithromycin in adult cystic fibrosis patients","volume":"38","author":"Beringer","year":"2004","journal-title":"Pediatric Pulmonology"},{"issue":"5","key":"10.1002\/14651858.CD002203.pub5-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00044011-200121050-00005","article-title":"Azithromycin concentrations in serum and bronchial secretions of patients with cystic fibrosis","volume":"21","author":"Cipolli","year":"2001","journal-title":"Clinical Drug Investigation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub5-BIB0076|cit76","first-page":"S24","article-title":"Laboratory and clinical effect of long-term roxithromycin treatment in adult patients with cystic fibrosis [abstract]","volume":"4","author":"Dionyssopoulou","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub5-BIB0077|cit77","first-page":"S21","article-title":"Effect of clarithromycin on inflammatory markers in bronchoalveolar lavage fluid in cystic fibrosis: a randomised, placebo-controlled crossover trial","volume":"3","author":"Dogru","year":"2004","journal-title":"Journal of Cystic Fibrosis"},{"issue":"5","key":"10.1002\/14651858.CD002203.pub5-BIB0078|cit78","first-page":"416","article-title":"Long-term clarithromycin in cystic fibrosis: effects on inflammatory markers in BAL and clinical status","volume":"51","author":"Do\u011fru","year":"2009","journal-title":"Turkish Journal of Pediatrics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub5-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/S1569-1993(10)60093-8","article-title":"Adherence behaviour of adult cystic fibrosis (CF) patients to prescribed azithromycin","volume":"9","author":"Elmasry","year":"2010","journal-title":"Journal of Cystic Fibrosis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub5-BIB0080|cit80","first-page":"A26","article-title":"Adherence behaviour of adult cystic fibrosis patients prescribed azithromycin","volume":"15","author":"Elmasry","year":"2010","journal-title":"Respirology"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0081|cit81","first-page":"Abstract no.: P","article-title":"An anti-inflammatory effect of azithromycin in cystic fibrosis","volume":"36 Suppl 54","author":"San Mok","year":"2010","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0082|cit82","unstructured":"Frederiksen B Koch C Hoiby N Pressler T Clinical efficacy of clarithromycin in CF patients with chronic lung infection Abstracts of the 24th European Cystic Fibrosis Conference; 2001 June 6-9; Vienna 2001 P208"},{"issue":"9100","key":"10.1002\/14651858.CD002203.pub5-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0140-6736(05)78360-4","article-title":"Long-term azithromycin may improve lung function in children with cystic fibrosis","volume":"351","author":"Jaffe","year":"1998","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub5-BIB0084|cit84","first-page":"S24","article-title":"Circulating phagocytes during zithromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection","volume":"4","author":"Moser","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0085|cit85","first-page":"514s","article-title":"Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic P. aeruginosa airway colonization","volume":"22 Suppl 45","author":"Kessaris","year":"2003","journal-title":"The European Respiratory Journal"},{"issue":"3","key":"10.1002\/14651858.CD002203.pub5-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1513\/AnnalsATS.201310-352OC","article-title":"Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis","volume":"11","author":"Nick","year":"2014","journal-title":"Annals of the American Thoracic Society"},{"issue":"1","key":"10.1002\/14651858.CD002203.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ppul.1085","article-title":"Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study","volume":"32","author":"Ordonez","year":"2001","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0088|cit88","first-page":"263","article-title":"Long term macrolide antibiotics improve pulmonary function in cystic fibrosis","volume":"28 Suppl 19","author":"Pirzada","year":"1999","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 33","key":"10.1002\/14651858.CD002203.pub5-BIB0089|cit89","first-page":"126s","article-title":"Immunoregulatory effect of a 14-membered ring macrolide antibiotic in cystic fibrosis patients","volume":"18","author":"Pukhalsky","year":"2001","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD002203.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/09629350410001688495","article-title":"Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease","volume":"13","author":"Pukhalsky","year":"2004","journal-title":"Mediators of inflammation"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0091|cit91","first-page":"274","article-title":"Increase of the sputum neutrophil elastase activity is a paradoxical effect of the successful lung disease treatment in cystic fibrosis","volume":"32 Suppl 22","author":"Pukhalsky","year":"2001","journal-title":"Pediatric Pulmonology"},{"issue":"Suppl 48","key":"10.1002\/14651858.CD002203.pub5-BIB0092|cit92","first-page":"P3758","article-title":"Anti-inflammatory therapy in cystic fibrosis: a comparative study in the treatment with nimesulide (selective cyclooxygenase-2 inhibitor) and clarithromycin (14-memebered ring macrolide antibiotic)","volume":"24","author":"Shmarina","year":"2004","journal-title":"European Respiratory Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002203.pub5-BIB0093|cit93","first-page":"S31","article-title":"Long-term low-dose therapy with macrolides in bronchopulmonary disease in Cystic Fibrosis (CF) pediatric patients","volume":"4","author":"Radionovitch","year":"2005","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0094|cit94","first-page":"S52","article-title":"The antinflammatory effect of clarithromycin in CF","volume":"2 (Suppl 1)","author":"Sriram","year":"2003","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0095|cit95","unstructured":"Use of repeated Multiple Breath Washout to detect and treat pulmonary exacerbation in children with Cystic Fibrosis, a multicenter randomized controlled study trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2019-003501-10-DK"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0096|cit96","first-page":"318","article-title":"Azithromycin in combination with inhaled colimycin and oral ciprofloxacin used for intermittent pseudomonas aeruginosa colonization in cystic fibrosis patients: results from a Scandinavian study","volume":"50 Suppl 41","author":"Hansen","year":"2015","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0097|cit97","unstructured":"Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00298922"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0098|cit98","unstructured":"Scandinavian Cystic Fibrosis Azithromycin Study Supplementary oral azithromycin in treatment of intermittent Pseudomonas aeruginosa colonization in CF-patients with inhaled colistin and oral ciprofloxacin; postponing next isolate of pseudomonas and prevention of chronic infection. A prospective, double-blinded, placebo-controlled scandinavian multi-centre study. A investigator initiated study - Scandinavian Cystic Fibrosis Azithromycin Study trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2006-003275-12-DK"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0099|cit99","unstructured":"Scandinavian cystic fibrosis azithromycin study clinicaltrials.gov\/show\/NCT00411736"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0100|cit100","unstructured":"Pukhalsky A Shmarina G Pukhalskaya D Perederko L Whether low frequency of hepatobiliary abnormalities in cystic fibrosis patients is associated with anti-inflammatory treatment? European Respiratory Society Annual Congress; 2008 Oct 4-8; Berlin, Germany 2008 216s"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0101|cit101","first-page":"27","article-title":"Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial","volume":"66 Suppl A","year":"2013","journal-title":"Japanese Journal of Antibiotics"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0102|cit102","unstructured":"Pittman JE Skalland MS Sagel SD Ramsey BW Mayer-Hamblett N Retsch-Bogart GZ Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas Journal of Cystic Fibrosis 10.1016\/j.jcf.2022.02.015"},{"issue":"6","key":"10.1002\/14651858.CD002203.pub5-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/ppul.21613","article-title":"Clarithromycin therapy for patients with cystic fibrosis: a randomized controlled trial","volume":"47","author":"Robinson","year":"2012","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0104|cit104","first-page":"339","article-title":"Clarithromycin therapy is not effective for the therapy of CF","volume":"46 Suppl 34","author":"Robinson","year":"2011","journal-title":"Pediatric Pulmonology"},{"issue":"6","key":"10.1002\/14651858.CD002203.pub5-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/BF01488805","article-title":"Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils","volume":"20","author":"Anderson","year":"1996","journal-title":"Inflammation"},{"issue":"2","key":"10.1002\/14651858.CD002203.pub5-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jcf.2012.07.006","article-title":"Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial","volume":"12","author":"Assael","year":"2013","journal-title":"Journal of Cystic Fibrosis"},{"issue":"6","key":"10.1002\/14651858.CD002203.pub5-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1177\/030006059101900603","article-title":"Azithromycin: an interim analysis","volume":"19","author":"Ball","year":"1991","journal-title":"Journal of International Medical Research"},{"issue":"1","key":"10.1002\/14651858.CD002203.pub5-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respiratory Medicine"},{"issue":"Pt 3","key":"10.1002\/14651858.CD002203.pub5-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/j.1469-7793.1999.0631u.x","article-title":"Molecular insights into the physiology of the 'thin film' of airway surface liquid","volume":"516","author":"Boucher","year":"1999","journal-title":"Journal of Physiology"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0110|cit110","unstructured":"CF Foundation Cystic Fibrosis Foundation Patient Registry 2021 Annual Data Report www.cff.org\/medical-professionals\/patient-registry"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0111|cit111","unstructured":"UK Cystic Fibrosis Registry Annual Data Report 2021 www.cysticfibrosis.org.uk\/sites\/default\/files\/2022-10\/CFT_2021-Annual-Data-Report-WEB.pdf"},{"issue":"15","key":"10.1002\/14651858.CD002203.pub5-BIB0112|cit112","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1002\/sim.1205","article-title":"Meta-analysis combining parallel and cross-over clinical trials. I: Continuous outcomes","volume":"21","author":"Curtin","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"15","key":"10.1002\/14651858.CD002203.pub5-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1002\/sim.1206","article-title":"Meta-analysis combining parallel and cross-over clinical trials. II: Binary outcomes","volume":"21","author":"Curtin","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"15","key":"10.1002\/14651858.CD002203.pub5-BIB0114|cit114","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1002\/sim.1207","article-title":"Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carryover","volume":"21","author":"Curtin","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0115|cit115","unstructured":"Deeks JJ Higgins JP Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"6","key":"10.1002\/14651858.CD002203.pub5-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.pupt.2009.03.002","article-title":"Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis","volume":"22","author":"Florescu","year":"2009","journal-title":"Pulmonary Pharmacology and Therapeutics"},{"issue":"1","key":"10.1002\/14651858.CD002203.pub5-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jcf.2008.09.001","article-title":"Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients","volume":"8","author":"Hansen","year":"2009","journal-title":"Journal of Cystic Fibrosis"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0118|cit118","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0119|cit119","unstructured":"Higgins JP Altman DG Sterne JA on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"issue":"6","key":"10.1002\/14651858.CD002203.pub5-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/thx.49.6.531","article-title":"Diffuse panbronchiolitis and cystic fibrosis: East meets West","volume":"49","author":"Hoiby","year":"1994","journal-title":"Thorax"},{"issue":"12","key":"10.1002\/14651858.CD002203.pub5-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S1286-4579(99)80518-8","article-title":"Pathogenicity of microbes associated with cystic fibrosis","volume":"1","author":"Hutchison","year":"1999","journal-title":"Microbes and Infection"},{"issue":"3","key":"10.1002\/14651858.CD002203.pub5-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000239440","article-title":"The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro","volume":"42","author":"Ichimiya","year":"1996","journal-title":"Chemotherapy"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/0924-8579(93)90039-8","article-title":"Therapeutic possibilities for diffuse panbronchiolitis","volume":"3","author":"Kobayashi","year":"1993","journal-title":"International Journal of Antimicrobial Agents"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/41.suppl_2.37","article-title":"Anti-inflammatory activity of macrolides: a new therapeutic potential?","volume":"41 Suppl B","author":"Labro","year":"1998","journal-title":"Journal Antimicrobial Chemotherapeutics"},{"issue":"7","key":"10.1002\/14651858.CD002203.pub5-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0092-8674(00)81724-9","article-title":"Evidence for periciliary liquid layer depletion, not abnormal ion composition in the pathogenesis of cystic fibrosis airways disease","volume":"95","author":"Matsui","year":"1998","journal-title":"Cell"},{"issue":"3","key":"10.1002\/14651858.CD002203.pub5-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1128\/AAC.38.3.528","article-title":"Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa","volume":"38","author":"Mizukane","year":"1994","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"5","key":"10.1002\/14651858.CD002203.pub5-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1093\/jac\/31.5.681","article-title":"Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics","volume":"31","author":"Molinari","year":"1993","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"4","key":"10.1002\/14651858.CD002203.pub5-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1093\/jac\/dkl014","article-title":"Macrolide resistance of Staphylococcus aureus and Haemophilus species associated with long-term azithromycin use in cystic fibrosis","volume":"57","author":"Phaff","year":"2006","journal-title":"Journal of Antimicrobial Chemotherapy"},{"issue":"6","key":"10.1002\/14651858.CD002203.pub5-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1378\/chest.08-1190","article-title":"Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection","volume":"135","author":"Quittner","year":"2009","journal-title":"Chest"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0130|cit130","unstructured":"Ratjen F Saiman L Mayer-Hamblett N Lands LC Kloster M Thompson V Effect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa Chest 10.1378\/chest.12-0628"},{"issue":"12","key":"10.1002\/14651858.CD002203.pub5-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1128\/AAC.31.12.1939","article-title":"Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms","volume":"31","author":"Retsema","year":"1987","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0132|cit132","unstructured":"Review Manager Web (RevMan Web) The Cochrane Collaboration 2023"},{"issue":"9","key":"10.1002\/14651858.CD002203.pub5-BIB0133|cit133","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001912.pub5","article-title":"Prophylactic anti-staphylococcal antibiotics for cystic fibrosis","author":"Rosenfeld","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0135|cit135","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD002203.pub5-BIB0136|cit136","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JP Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD002203.pub5-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/01.inf.0000247109.44249.ac","article-title":"Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function","volume":"26","author":"Tramper-Stranders","year":"2007","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"1","key":"10.1002\/14651858.CD002203.pub5-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1164\/ajrccm.155.1.9001333","article-title":"Effect of clarithromycin on lymphocytes in chronic respiratory Pseudomonas aeruginosa infection","volume":"155","author":"Yanagihara","year":"1997","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002203.pub5-BIB0139|cit139","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002203","article-title":"Macrolide antibiotics for cystic fibrosis (Cochrane Review)","author":"Southern","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD002203.pub5-BIB0140|cit140","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002203.pub2","article-title":"Macrolide antibiotics for cystic fibrosis (Cochrane Review)","author":"Southern","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD002203.pub5-BIB0141|cit141","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002203.pub3","article-title":"Macrolide antibiotics for cystic fibrosis","author":"Southern","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T20:11:43Z","timestamp":1744575103000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002203.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,2,27]]},"references-count":141,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002203.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,27]]}}}